We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Scynexis’ Antifungal Drug Gains FDA Approval for Yeast Infections
Scynexis’ Antifungal Drug Gains FDA Approval for Yeast Infections
Scynexis has secured FDA approval for Brexafemme (ibrexafungerp) as an oral treatment for vaginal yeast infections, making it the first FDA-approved drug in a novel antifungal class in more than 20 years, according to the company.